MIST Milestone Pharmaceuticals Inc. Common Shares

XNAS 0.64 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

MIST $0.64 —
Key stats
$0.64
Pre-market $0.64 -0.84%
52-Week Range
$0.63 – $3.06
YTD
-68.57%
Straddle Price
$0.57
P/C Vol Ratio
0.10
Market Cap
$0.1B
Open
$0.65
Day Range
$0.63 – $0.67
Volume
802,492
Prev Close
$0.65
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.31
Cost of Equity (CAPM)12.17% (VRP-adj)
WACC9.34%
Volatility Risk Premium+307.9pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)224.4%
Book / Price-49.2%
Gross Margin (TTM)98.0%
FCF Margin (TTM)-2631.1%
Quality Score2/6 — normal (10y DCF)
SMA 50$0.92 (Market Anchor value)
SMA 20 / Bollinger Mid$0.75
Bollinger Width / SMA204100.8% (drives anchor stability)
Net Debt$-0.1B
Market Cap$0B
Peers used for multiples: ABEO, ACHV, CLDX, CMPS, CORT, DCTH, KYTX, PHAT
60-Day Conviction
91%
20-Day Fair Value
≈ by Nov 25, 2026
$0.65
α +0.7% rank 77%
conviction
43%
40-Day Fair Value
≈ by Dec 24, 2026
$0.66
α +2.7% rank 78%
conviction
81%
60-Day Fair Value
≈ by Jan 22, 2027
$0.67
α +4.3% rank 73%
conviction
91%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B n/a 0% median 3.7× · 6 peers
Peer P/S $0.20 16% median 9.9× · 5 peers
Market Anchor (SMA50) $0.92 84% stability 79% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.1B
Employees
38
List Date
2019-05-09
CIK
0001408443
Next Earnings
2026-11-11 (After-Close)
EPS Forecast
($0.20) (4 est.)
Headquarters
Montreal, A8
Homepage
https://www.milestonepharma.com

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan9.17%-3.88%-9.63%-11.11%-9.22%-6.83%-5.25%
Feb-4.52%-24.43%-21.39%0.60%-16.84%-12.76%-13.22%
Mar-22.90%31.02%25.48%11.18%-51.51%-31.21%-6.32%
Apr-3.14%-2.92%-8.79%-9.84%73.68%37.40%14.40%
May-0.33%-8.78%8.84%-6.25%22.73%-24.06%-1.31%
Jun-5.66%13.26%-22.97%-12.58%12.14%-1.47%-2.88%
Jul1.42%27.13%-3.58%7.46%-22.87%-16.23%-1.11%
Aug4.84%18.63%-15.46%2.16%28.67%3.57%7.07%
Sep-7.46%4.55%14.81%9.35%8.70%-24.06%0.98%
Oct-0.18%-44.65%-14.09%-3.33%-6.34%-21.00%*-14.93%
Nov-4.04%-2.58%19.29%38.19%45.41%--19.25%
Dec16.13%-18.52%-47.32%18.00%-24.91%---11.32%
Total-19.89%-33.87%-65.56%39.02%-3.47%-70.08%-25.64%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $0.75
SMA 50: $0.92
SMA 200: $1.40
Current: $0.64
EMA 12: $0.72
EMA 26: $0.78
MACD: -0.0690 | Signal: -0.0013
BEARISH
ADX (14): 35.03
TREND
+DI: 9.67
−DI: 25.81

Momentum Oscillators

RSI (14): 30.48
NEUTRAL
Stoch %K: 8.32
Stoch %D: 7.07
Williams %R: -92.53

Volume & Volatility

BB Upper: $0.87
BB Lower: $0.64
NEUTRAL
OBV: -191,771,168
Vol SMA 20: 986,191
Vol ROC: -31.59%
ATR: $0.06
True Range: $0.04
HV 20: 76.6%
HV 30: 69.8%
HV 60: 69.0%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: BEARISH (Confidence Level: 7/10) Key Drivers: * Technical indicators suggest a bearish trend, with MACD in a bearish configuration and RSI indicating overbought conditions. * Recent news headlines highlight positive developments for the company, but these have not been reflected in the stock price. Primary Risks: * High volatility and beta of 2.40 make the stock more susceptible to large moves. Recent News Sentiment Impact: * Positive news sentiment has been present since the last earnings report, but this has not translated into a significant increase in the stock price.

Technical Analysis

Trend Direction: Bearish (Short-term), Bearish (Medium-term), Neutral (Long-term) Support/Resistance Levels: * Upper Bollinger Band: $1.27 * Middle Bollinger Band: $1.13 * Lower Bollinger Band: $1.00

Momentum Signals: * RSI (14): 54.10 (neutral) * MACD: -0.02 / Signal: 0.01 / Histogram: -0.03 (bearish) * Stochastic %K: 58.02 * Stochastic %D: 40.53

Volume Analysis: * Volume SMA 20: 1708996.05 * On-Balance Volume (OBV): -170930151.83 * Volume Rate of Change: -41.68%

News & Sentiment Analysis

Recent Headlines Summary: The recent news headlines highlight positive developments for the company, including FDA approval and successful clinical trials.

Sentiment Assessment: NEUTRAL with a slight positive bias

Catalyst Identification: Upcoming events or catalysts are not immediately apparent.

Market Narrative: The market narrative is that the stock has been trading sideways despite positive news flow, suggesting potential bearish sentiment.

Risk & Volatility Assessment

Beta Interpretation: High risk (beta >1.5)

Volatility Regime: Current vs historical volatility levels indicate high volatility

Options Market Signals: IV Rank: 40.9% (Medium - shows if volatility is historically high/low) Current IV: 250.5% Expected Move: $0.23 (22 DTE), 7-DTE: $0.23 Volume Flow: 84 calls vs 120 puts Open Interest: 14,568 calls vs 724 puts Put/Call Volume Ratio: 1.43 (Bearish sentiment) Put/Call OI Ratio: 0.05

Downside Protection: Support levels and risk management considerations suggest a potential downside move to the lower Bollinger Band.

Market Context & Positioning

Sector Performance: The healthcare sector has been trading sideways recently, suggesting some caution.

Institutional Activity: Volume patterns suggest institutional interest is present but not driving significant moves.

Correlation Analysis: The stock is highly correlated with the market (R-squared interpretation: 0.85).

Relative Valuation: The stock is positioned within a trading range and may need a catalyst to break out.

Key Levels & Action Items

Critical Price Levels: * Lower Bollinger Band: $1.00 * Upper Bollinger Band: $1.27

Breakout/Breakdown Levels: * Breakout above the upper Bollinger Band could trigger a significant move. * Breakdown below the lower Bollinger Band could indicate further bearish momentum.

Time-Sensitive Catalysts: Earnings dates, FDA approvals, and product launches are not immediately apparent.

Risk Management: Stop-loss levels and position sizing considerations suggest a cautious approach to avoid potential losses.

Please note that this analysis is based on the provided data and should be used as a reference only.

Generated
News
All MIST news →
Showing 1–10 of 50
Page 1 of 5
Earnings History
13 of 13 under expected move
Avg Expected Move
53.30%
Avg Actual Move
4.23%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2022-08-10 After-Close 9.27% 7.88% 0.85x Within
2022-11-10 After-Close 17.86% 3.12% 0.17x Within
2023-08-10 After-Close 58.79% 3.94% 0.07x Within
2023-11-13 After-Close 17.52% 4.27% 0.24x Within
2024-08-08 After-Close 265.96% 0.00% 0.00x Within
2024-11-12 After-Close 49.47% 1.60% 0.03x Within
2025-03-13 After-Close 66.50% 6.90% 0.10x Within
2025-05-14 After-Close 61.97% 1.71% 0.03x Within
2025-08-12 Pre-Market 14.52% 7.10% 0.49x Within
2025-11-12 Pre-Market 52.36% 1.05% 0.02x Within
2026-03-20 After-Close 25.74% 7.35% 0.29x Within
2026-05-13 After-Close 21.80% 5.23% 0.24x Within
2026-08-12 After-Close 31.11% 4.89% 0.16x Within

Earnings calendar: this week’s reports with expected vs actual moves →

MIST Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $0.57
7-DTE Move: $0.57
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 31
Put Volume: 3
P/C Volume: 0.097
BULLISH
Call OI: 1,756
Put OI: 10
P/C OI: 0.006
Total OI: 1,766

ATM Options Pricing

ATM Call: $0.42
ATM Put: $0.15
Call %: 66.0%
Put %: 23.3%

Chain Summary

Chain Volume: 963
Chain OI: 21,464
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 51st percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
51%
vs own history
GEX tilt
+0.99
OI-weighted, today
Vanna tilt
+0.99
δ-sensitivity to IV
Charm tilt
-0.99
δ-decay vs time
Vanna tilt +0.99: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.99: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 4 ATM contracts, 2k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 431.0% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$0.57Oct 26
Beta Analysis

Risk Metrics

Beta: 2.4551
Alpha: -111.86%
Correlation: 0.4219
R-Squared: 17.8%
Stock Volatility: 74.2%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own MIST
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Point72 Hedge fund
Steve Cohen
$7.3M
0.01%
#867 of 1945+398.4%13F
Millennium Management Hedge fund
Izzy Englander
$4.2M
0.00%
#2158 of 3716+103.5%13F
Citadel Hedge fund
Ken Griffin
$44K
0.00%
#6034 of 6285-83.3%13F
Rockefeller Capital Management Family office
Rockefeller family
$17K
0.00%
#3801 of 47290.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

MIST Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 117,960,822 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

83 filers50,984,822 shares$67.83M value43.22% of float
# Filer Shares Value % of Total % of Float Period
1 Pavaki Capital Management LLC 9,067,848 $12.15M 17.91% 7.69% 2026-06-30
2 RTW INVESTMENTS, LP 7,833,336 $10.50M 15.48% 6.64% 2026-06-30
3 Propel Bio Management, LLC 7,429,590 $9.96M 14.68% 6.30% 2026-06-30
4 Point72 Asset Management, L.P. 5,411,138 $7.25M 10.69% 4.59% 2026-06-30
5 Simplify Asset Management Inc. 3,349,379 $4.49M 6.62% 2.84% 2026-06-30
6 Millennium Management LLC Custodian 3,142,219 $4.21M 6.21% 2.66% 2026-06-30
7 Two Sigma Investments, LP Custodian 2,040,015 $2.73M 4.03% 1.73% 2026-06-30
8 Marshall Wace, LLP Custodian 1,797,695 $2.41M 3.55% 1.52% 2026-06-30
9 Kalehua Capital Management LLC 1,269,237 $1.70M 2.51% 1.08% 2026-06-30
10 Lion Point Capital, LP 820,000 $1.10M 1.62% 0.70% 2026-06-30
11 TORONTO DOMINION BANK 750,000 $1.00M 1.48% 0.64% 2026-06-30
12 RVW Wealth, LLC 1,148,260 $994.05K 1.47% 0.97% 2026-09-30
13 Ameriprise Financial, Inc. Custodian 666,666 $893.33K 1.32% 0.57% 2026-06-30
14 Boxer Capital Management, LLC 666,666 $893.33K 1.32% 0.57% 2026-06-30
15 Morgan Stanley Custodian 635,211 $851.18K 1.25% 0.54% 2026-06-30
16 UBS Group AG Custodian 465,403 $623.64K 0.92% 0.39% 2026-06-30
17 BOOTHBAY FUND MANAGEMENT, LLC 462,669 $619.98K 0.91% 0.39% 2026-06-30
18 Susquehanna International Group, LLP Custodian 359,895 $482.26K 0.71% 0.31% 2026-06-30
19 AMH Equity Ltd 231,671 $463.34K 0.68% 0.20% 2025-09-30
20 Aptus Capital Advisors, LLC 339,450 $454.86K 0.67% 0.29% 2026-06-30
21 GUARDIAN WEALTH ADVISORS, LLC / NC 339,450 $454.86K 0.67% 0.29% 2026-06-30
22 Seven Fleet Capital Management LP 270,233 $362.11K 0.53% 0.23% 2026-06-30
23 Squarepoint Ops LLC 231,824 $310.64K 0.46% 0.20% 2026-06-30
24 LPL Financial LLC Custodian 220,873 $295.97K 0.44% 0.19% 2026-06-30
25 Balyasny Asset Management L.P. 220,498 $295.47K 0.44% 0.19% 2026-06-30
7 filers$288.77K notional
# Filer Notional Value % of Total Period
1 Simplex Trading, LLC Custodian $78.79K 27.29% 2026-06-30
2 Citadel Advisors LLC Custodian $75.17K 26.03% 2026-06-30
3 GROUP ONE TRADING LLC Custodian $65.12K 22.55% 2026-06-30
4 IMC-Chicago, LLC Custodian $31.09K 10.77% 2026-06-30
5 Jane Street Group, LLC Custodian $21.44K 7.42% 2026-06-30
6 Susquehanna International Group, LLP Custodian $16.48K 5.71% 2026-06-30
7 Aptus Capital Advisors, LLC $670 0.23% 2026-06-30
6 filers$336.74K notional
# Filer Notional Value % of Total Period
1 Citadel Advisors LLC Custodian $220.16K 65.38% 2026-06-30
2 Jane Street Group, LLC Custodian $41.81K 12.42% 2026-06-30
3 Susquehanna International Group, LLP Custodian $30.28K 8.99% 2026-06-30
4 IMC-Chicago, LLC Custodian $26.40K 7.84% 2026-06-30
5 Simplex Trading, LLC Custodian $11.12K 3.30% 2026-06-30
6 GROUP ONE TRADING LLC Custodian $6.97K 2.07% 2026-06-30

MIST Insider Trading (Form 4)

Latest: 2026-06-12
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-12 Michael John Tomsicek Director Grant (A) +77,000 opt — EDGAR
2026-06-12 Joseph C Papa Director Grant (A) +77,000 opt — EDGAR
2026-06-12 Seth H. Z. Fischer Director Grant (A) +77,000 opt — EDGAR
2026-06-12 Lisa M. Giles Director Grant (A) +77,000 opt — EDGAR
2026-06-12 Robert James Wills Director Grant (A) +77,000 opt — EDGAR
2026-06-12 Andrew Saik Director Grant (A) +77,000 opt — EDGAR
2026-06-12 Stuart Duty Director Grant (A) +77,000 opt — EDGAR
2026-04-20 Joseph Oliveto President and CEO Sell (S) −36,500 $2.26 -$82.5K EDGAR
2026-02-05 David Bharucha Chief Medical Officer Grant (A) +204,000 opt — EDGAR
2026-02-05 Jeffrey Edward Nelson Chief Operating Officer Grant (A) +204,000 opt — EDGAR
2026-02-05 Joseph Oliveto President and CEO Grant (A) +679,000 opt — EDGAR
2026-02-05 Lorenz Muller Chief Commercial Officer Grant (A) +204,000 opt — EDGAR
2026-02-05 Amit Hasija CFO & EVP of Corp. Development Grant (A) +204,000 opt — EDGAR
2026-02-04 Joseph Oliveto President and CEO Grant (A) +1,132,000 RSU — EDGAR
2026-02-04 David Bharucha Chief Medical Officer Grant (A) +340,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

MIST Insider Holdings

9 insiders · @ $0.64
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Joseph Oliveto President and CEO 446,244 $287.6K -$555.7K 12 2026-04-20
2 Lorenz Muller Chief Commercial Officer 196,486 $126.6K -$145.9K 12 2026-02-05
3 David Bharucha Chief Medical Officer 125,426 $80.8K -$110.8K 8 2026-02-05
4 Joseph C Papa Director 100,000 $64.4K $0 4 2026-06-12
5 Jeffrey Edward Nelson Chief Operating Officer 100,000 $64.4K -$158.2K 5 2026-02-05
6 Amit Hasija CFO & EVP of Corp. Development 91,993 $59.3K -$158.2K 11 2026-02-05
7 Robert James Wills Director 65,000 $41.9K $74.0K 9 2026-06-12
8 Debra K. Liebert Director 20,793 $13.4K $73.9K 8 2025-07-15
9 Michael John Tomsicek Director 15,000 $9.7K $79.8K 8 2026-06-12
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

MIST Board & Officers

As of SEC filings through Jun 12, 2026

Directors 9

Officers 6

Changes in the last 10 years (32)
Mar 17, 2026David I. Sandoval became GC & Chief Compliance Officer
Sep 3, 2024Joseph C Papa became a director
Jul 15, 2024Stuart Duty became a director
Jul 15, 2024Andrew Saik became a director
Mar 24, 2023Rtw Investments, LP reported in an SEC filing no longer being a 10% owner
Mar 24, 2023Roderick Wong reported in an SEC filing no longer being a 10% owner
Mar 21, 2023Seth H. Z. Fischer became a director
Aug 9, 2022Jeffrey Edward Nelson became Chief Operating Officer
Feb 15, 2022David Bharucha became Chief Medical Officer
Oct 1, 2020Robert James Wills became a director
Oct 1, 2020Lisa M. Giles became a director
Jul 30, 2020De Solidarite Des Travailleurs Du Quebec Fonds reported in an SEC filing no longer being a 10% owner
Nov 27, 2019Novo Holdings A/S reported in an SEC filing no longer being a 10% owner
Nov 11, 2019Richard C Pasternak became a director
Sep 9, 2019Amit Hasija became CFO & EVP of Corp. Development
May 14, 2019Novo Holdings A/S first listed as a 10% owner in an SEC filing
May 8, 2019Timothy Maness became Vice President, Finance
May 8, 2019Rtw Investments, LP became a 10% owner
May 8, 2019Roderick Wong became a 10% owner
May 8, 2019Philippe Douville became Chief Scientific Officer
Not reported recently (9)
  • Richard C Pasternak · Last reported as a director in an SEC filing dated Jun 9, 2023
  • Paul F Truex · Last reported as a director in an SEC filing dated Jun 1, 2022
  • Francis Plat · Last reported as Chief Medical Officer in an SEC filing dated Mar 26, 2021
  • Paul R Edick · Last reported as a director in an SEC filing dated Jun 8, 2020
  • Timothy Maness · Last reported as Vice President, Finance in an SEC filing dated Sep 11, 2019
  • Philippe Douville · Last reported as Chief Scientific Officer in an SEC filing dated May 14, 2019
  • Bdc Capital Inc. · Last reported as a 10% owner in an SEC filing dated May 9, 2019
  • Nilesh Kumar · Last reported as a director in an SEC filing dated May 8, 2019
  • Marco Boorsma · Last reported as a director in an SEC filing dated May 8, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

MIST Proposed Insider Sales (Form 144)

Latest: 2026-04-16
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-04-16 JOSEPH OLIVETO Director, Officer 36,500 $80.3K 2026-04-16 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-01-08 JOSEPH OLIVETO Director, Officer 79,500 $170.9K 2026-01-08 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-01-07 JOSEPH OLIVETO Officer 500 $1.0K 2026-01-07 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
2 ETFs hold MIST
2 shown · $4.51M total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 SURI Simplify Propel Opportunities ETF Nport 5.81% $4.5M — 2026-06-30
2 GWX State Street® SPDR® S&P® International Small Cap ETF SPDR (State Street) 0.00% $17,741 $896.9M 2026-10-23
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.69
TTM Revenue
$2.34M
TTM Net Income
$-84.01M
TTM Op. Cash Flow
$-61.29M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$559.00K$-28.61M$-0.21$-22.71M
Q1 '262026-03-31$238.00K$-26.07M$-0.20$-16.05M
Q4 '252025-12-31$1.55M$-17.41M$-0.15$-12.78M
Q3 '252025-09-30—$-11.92M$-0.12$-9.75M
Q2 '252025-06-30$0.00$-12.97M$-0.20$-12.57M
Q1 '252025-03-31—$-20.76M$-0.31$-13.95M
Q4 '242024-12-31—$-12.36M$-0.19$-6.84M
Q3 '242024-09-30—$-9.44M$-0.14$-7.02M
Q2 '242024-06-30—$-9.36M$-0.14$-6.05M
Q1 '242024-03-31—$-10.35M$-0.21$-8.93M
Q4 '232023-12-31$0.00$-13.61M$-0.32$-9.80M
Q3 '232023-09-30—$-15.08M$-0.35$-12.16M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-12
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
32.44
EV/EBITDA
—
EV/Sales
-14.73
ROE
—
ROA
-46.3%
Div Yield
0.00%
FCF Yield
-80.63%
Debt/Equity
—
Current Ratio
—
Market Cap
$76.01M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
19.01M
SI % of Float
17.27%
Days to Cover
15.98
Short Vol Ratio
48.5%
Free Float
110.04M
Float %
88.4%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14